Mesoblast Limited (MEOBF)
| Previous Close | 0.4800 |
| Open | 0.4800 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.4800 - 0.4800 |
| 52 Week Range | 0.4400 - 1.5000 |
| Volume | |
| Avg. Volume | 1,358 |
| Market Cap | 312.218M |
| Beta (5Y Monthly) | 2.22 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Mesoblast Key Opinion Leader Event Series for Investors & Analysts
Chronic Low Back Pain due to Degenerative Disc DiseaseNEW YORK, June 09, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webinar focused on the current treatment landscape and unmet medical need for patients with chronic low back pain (CLBP) due to degenerative disc disease, a condition associated with local inflammation in the disc. The webinar will feature presentations from Key Opinion Lea
- GlobeNewswire
Operational Highlights and Financial Results for the Period Ended March 31, 2022
Substantial Reduction in Operational Spend while Maintaining Focus on BLA ResubmissionNEW YORK, May 31, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB) global leader in allogeneic cellular medicines for inflammatory diseases, today reported financial results and operational highlights for the period ended March 31, 2022. Financial Highlights Net cash usage reported for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with U
- GlobeNewswire
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended March 31, 2022NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an activity report for the third quarter ended March 31, 2022. Financial highlights Net cash usage for operating activities in the quarter was reduced by 40%, or US$10.3 million, to US$15.5 million compared with US$25.8 million in the comparativ
